{"summary": "cDNA of CSBF/C10orf99 contains typical polyadenylation signal (AATAAA) within the 3' UTR and Kozak sequence (CACCATG)39 within the 5' UTR. transmembrane helices domain is located in the signal peptide. Western blot assay of CSBF/C10orf99 was using mouse anti-human antibody. hek 293T cells transfected with pwYD11-CSBF-Fc were cultured in absence or presence of 10 g/ml of BFA. the supernatants and cell lysates were prepared 48 hours post-transfection. CSBF/C10orf99 is a ligand of SUSD2 Collectively, the above findings verified that CSBF/C10orf99 is a classical secreted protein. previous studies deduced high-confidence interactions between CSBF/C10orf99 and SUSD2 as well as Gal1 and SUSD243. all these mutants are abundant in cytoplasm, suggesting that absence of any of these four domains would change the localization of this protein. the following studies only included the function of intact SUSD2 protein. ly expressing SUSD2-EGFP were treated with CSBF/C10orf99 (0, 10, 100 and 500 ng/ml) at 37\u00b0C for 30 minutes. the data shown are representative of at least three independent experiments. CSBF/C10orf99 can bind SUSD2 and trigger receptor internalization. the fluorescence energy could transfer from EGFP to RFP when the distance between them was less than 10 nm. human galectin-1 (Gal1) was used as a positive ligand control. CSBF/C10orf99 and SUSD2 are decreased in colorectal cancer tissues. mRNA was found to be expressed at the highest level in colon, at moderate level in tonsil, and almost undetectable in other tissues. expression of CSBF/C10orf99 was carried out using RT-PCR. APDH was detected as a reference gene in primary colorectal cancers by real-time PCR. N/C, paired adjacent tissues/cancer tissues. GAPDH was detected as a reference gene. human protein Atlas reported that SUSD2 is down-regulated in colorectal cancer tissues. we investigated the expression pattern of SUSD2 in normal human tissues. CSBF/C10orf99 and SUSD2 are decreased in colon cancer cell lines. CSBF/C10orf99 interacts with SUSD2 to inhibit colon cancer cell growth. CSBF/C10orf99 and SUSD2 are both down-regulated in colon cancer tissues and cell lines. the data shown are representative of at least three independent experiments. co-expression of CSBF/C10orf99 and SUSD2 inhibited colony formation in LoVo cells. assays were performed in triplicate, and mean SD are shown. CSBF/C10orf99 could significantly increase the growth inhibitory effect of SUSD2 but not in LoVo-Neo cells. CSBF/C10orf99 interacts with SUSD2 to induce G1 cell cycle arrest. CSBF/C10orf99 was co-expressed with SUSD2 in LoVo cells. cyclin D1, cyclin D3 and CDK6 were down-regulated in CSBF/C10orf99 and SUSD2 co-expressing LoVo cells, consistent with the phenotypes of G1 cell cycle arrest. cDNA of CSBF/C10orf99 contains typical polyadenylation signal (AATAAA) within the 3' UTR and Kozak sequence (CACCATG)39 within the 5' UTR. transmembrane helices domain is located in the signal peptide. the data shown are representative of at least three independent experiments. Western blot assay of CSBF/C10orf99 was using mouse anti-human IgG antibody. the results showed that CSBF-myc-His was in the lumen of intracellular compartment along the classic secretion pathway. we detected CSBF-Fc protein in the cell culture supernatant transfected with pwYD11-CSBF-Fc plasmid and then performed a BFA inhibition assay. CSBF/C10orf99 is a classical secretory protein. compared with the wild type of SUSD2, all these mutants are abundant in cytoplasm. this suggests that absence of any of these four domains would change the localization of this protein, which may further affect its function. the following studies only included the function of intact SUSD2 protein. CSBF/C10orf99 induced internalization of SUSD2-EGFP in a dose-dependent manner. CSBF/C10orf99 was fixed and stained with Hoechst 33258. the data shown are representative of at least three independent experiments. the internalized SUSD2-EGFP was located in the endosome. CSBF/C10orf99 can bind SUSD2 and trigger receptor internalization. the fluorescence energy could transfer from EGFP to RFP when the distance between them was less than 10 nm. CSBF/C10orf99 and SUSD2 are decreased in colorectal cancer tissues. mRNA was found to be expressed in specific tissues at the highest level in colon, at moderate level in tonsil, and almost undetectable in other tissues. the expression of CSBF/C10orf99 was dramatically reduced in most of the primary cancer tissues compared with that in the adjacent tissues. the expression of CSBF/C10orf99 was dramatically reduced in most of the primary cancer tissues compared with that in the adjacent tissues. CSBF/C10orf99 and SUSD2 are decreased in colon cancer cell lines with different patterns of gene regulation. expression of CSBF/C10orf99 and SUSD2 in six cell lines was carried out using real-time PCR. cDNA of colon tissue from Clontech was used as positive control. CSBF/C10orf99 interacts with SUSD2 to inhibit colon cancer cell growth. CSBF/C10orf99 and SUSD2 are both down-regulated in colon cancer tissues. a new tab (a) shows that cell growth was inhibited by co-expression of CSBF/C10orf99 and SUSD2 in HCT116 and LoVo cells. the data shown are representative of at least three independent experiments. the colony of SUSD2 single-expressed cells was also less than that of vector control cells. CSBF/C10orf99 could significantly increase the growth inhibitory effect of SUSD2 but not in LoVo-Neo cells. cyclin D1, cyclin D3 and CDK6 were down-regulated in CSBF/C10orf99 and SUSD2 co-expressing LoVo cells. the expression of cyclin B1 was not changed, consisting with the undetectable change of G2/M phase. the results were expressed as Mean S.D. of three independent experiments. cytokine CSBF/C10orf99 is a classical secreted protein with a regular N-terminal signal peptide of 24 amino acids. recombinant sSUSD2 is indispensable for the growth inhibitory effect of CSBF/C10orf99 on colon cancer cells. this is the first systemic study of CSBF/C10orf99. further studies are necessary to elucidate the function of CSBF/C10orf99 in Th1 cell immune responses. expressional and functional characteristics of CSBF/C10orf99 indicate it may be a tumor suppressor. it is located on chromosome 10q23.1 beside the genomic region of tumor suppressor PTEN (10q23.3)52. ectopic expression of Susd2 can inhibit growth and reverse tumorigenic phenotypes of HT1080 cells and HeLa cells in vitro55,56. their results indicated that Susd2 is a possible tumor suppressor. the interaction of SUSD2 with Gal1 increased the invasion of breast cancer cells. hek 293T, HCT116, HT29, LoVo, SW480, SW620 and RKO cells were obtained from our collaborators. CSBF/C10orf99 was synthesized in Chinese Peptide Company (Hangzhou, China) with a purity > 97%. CSBF/C10orf99 and SUSD2 CSBF/C10orf99 were amplified by PCR. plasmid was digested with EcoRI and KpnI and cloned into pEGFP-N1. plasmid was digested with EcoRI and BamHI and ligated into pcDNA3.1(-)-myc-His. truncated plasmids of SUSD2-HA were constructed by standard method of site-directed mutagenesis. cells were seeded on coverslips for 24 hours. at 24 hours post-transfection, cells were seeded on coverslips for 24 hours. cells were washed and fixed for 20 minutes with prepared 4% PFA. anti-myc (9E10), anti-Human IgG (Fc specific), anti-HA (C29F4), anti-cyclin D1, anti-cyclin D3, anti-CDK4, anti-CDK6, anti-phospho-Cyclin B1 (Ser147), anti-SUSD2 rabbit polyclonal antibody, anti-tublin, anti-GAPDH and IRDye secondary antibodies. hek 293T cells were seeded on coverslips for 24 hours. cells were transfected with EGFP-mCherry, EGFP, mCherry, CSBF-mCherry, Gal1-mCherry, SUSD2-EGFP, EGFP+CSBF-mCherry, EGFP+Gal1-mCherry, SUSD2-EGFP+mCherry, SUSD2-EGFP+mCher the supernatant was removed and the bound radioligand was counted in a liquid scintillation gamma-counter. 125I-CSBF was added to the binding reaction with 7 appropriate concentrations. primers for SUSD2 amplification were using 5'-AGAGCTGGATGGACCTGAAA-3' and 5'-ATGCCAGCATGAGAGAC-3'. all samples were normalized against GAPDH using comparative Ct method. Flow cytometry For SUSD2 expression analysis, fixed and permeabilized cells were stained with mouse monoclonal W5C5 antibody (Catalog #327401, BioLegend) or the appropriate isotype control (mouse IgG1, kappa) Labeled cells were used for flow cytometric analysis by FACSCalibur (BD Biosciences) anti-Human IgG (Fc specific), anti-cyclin D1 (# 2926, Cell Signaling Technology), anti-CDK4 (# 2906, Cell Signaling Technology), anti-phospho-Cyclin B1 (Ser147), anti-SUSD2 rabbit polyclonal antibody (# HPA004117, Sigma-Aldrich), anti-tublin (# T8328, Sigma-Aldrich) and anti-GAPDH (# 2118, Cell pcDNA3.1-CSBF-myc-His, pCMV-CSBF-Flag and pwYD11-CSBF-Fc were amplified from HCT116 cDNA library. the plasmid was constructed using the full-length SUSD2 as a template for PCR with a pair of primers. jugated secondary antibodies were applied for detection. cells were incubated for 60 minutes with 0.05 g/ml dye (Sigma-Aldrich) coverslips were mounted, sealed and examined under a confocal laser scanning microscope. cells containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM EDTA (pH 8.0) and protease inhibitor cocktail were incubated overnight at 4\u00b0C with anti-HA or anti-Flag. after intensive washing and centrifugation, immune complexes were analysed by Western blotting. EGFP (488 nm excitation; 510 nm emission) and mCherry (514 nm excitation; 600 nm emission) over 10 cells were gained in each group. 125I-Gal1 was added to the binding reaction with unlabeled CSBF of 7 appropriate concentrations. CSBF/C10orf99 amplification was carried out using the following primers: 5'-CTCCACAGAGAAGGGAAGAGGCG-3' and 5'-GGACCACTGGATGCTGGT-3' and 5'-CAGAGGGAGAGGGG-3. amplification conditions were 10 min initial denaturation at 95\u00b0C followed by 40 cycles of each 15 s at 95\u00b0C. mation Envision System HRP (DakoCytomation, USA) was applied for 30 min. all slides were visualized with 0.05% (w/v) 3,3\u2032-diaminobenzidine. cell proliferation assay Cells were harvested, plated in 96-well plates. p 0.05 was considered statistically significant. * = p 0.05, ** = p 0.01, and *** = p 0.001. authors reviewed the manuscript."}